All In Biotech

Drug Trial Radar · NCT05501886

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy

Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 701 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

701

Planned (sponsor's estimate)

Start

Dec 8, 2022

Primary completion

Jun 30, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Celcuity IncIndustry
Sponsor type
Industry
First posted
Aug 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.

Conditions

  • Breast Cancer

Interventions

  • GedatolisibDrug

    Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off

  • PalbociclibDrug

    Palbociclib 125 mg PO given daily for 3 weeks (21 days), followed by 1 week off

  • FulvestrantDrug

    Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1

  • AlpelisibDrug

    Alpelisib 300 mg PO (2 × 150 mg tablets) given daily for 4 weeks (28 days)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) in Patients with PIK3CA WT and PIK3CA MT Breast CancerTime frame: Approximately 48 months

Locations

235 sites in 23 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Arizona Oncology (US Oncology/McKesson) - Goodyear

    Goodyear, Arizona

  • St. Bernards Medical Center

    Jonesboro, Arkansas

  • CARTI Cancer Center

    Little Rock, Arkansas

  • Pacific Cancer Medical Center Inc

    Anaheim, California

  • Kaiser Permanente South Bay Medical Center

    Harbor City, California

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California

  • Pacific Cancer Care

    Monterey, California

  • University of California, Irvine Medical Center

    Orange, California

  • Ventura County Hematology Oncology Specialists

    Oxnard, California

  • Redlands Hematology Oncology

    Redlands, California

  • UCLA Hematology/Oncology-Santa Monica

    Santa Monica, California

  • Torrance Memorial Physician Network - Cancer Care

    Torrance, California

  • Kaiser Permanente Medical Center - Vallejo

    Vallejo, California

  • PIH Health Hospital Whittier

    Whittier, California

  • Yale Cancer Center - New Haven

    New Haven, Connecticut

  • South Broward Hospital District d/b/a Memorial Healthcare System

    Hollywood, Florida

  • Cancer Specialists of North Florida - Jacksonville

    Jacksonville, Florida

  • H. Lee Moffitt Cancer Center & Research Institute

    Tampa, Florida

  • Bond & Steele Clinic, P.A. d/b/a Bond Clinic, P.A.

    Winter Haven, Florida

  • John D. Archbold Memorial Hospital

    Thomasville, Georgia

  • Illinois Cancer Specialists - Arlington Heights

    Arlington Heights, Illinois

  • Fort Wayne Medical Oncology and Hematology

    Fort Wayne, Indiana

  • University of Kansas Cancer Center

    Westwood, Kansas

  • University of Kentucky Medical Center

    Lexington, Kentucky

  • Mercy Health - Paducah

    Paducah, Kentucky

  • American Oncology Partners of Maryland, PA

    Bethesda, Maryland

  • Maryland Oncology Hematology, P.A. - Rockville

    Rockville, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Henry Ford Hospital

    Detroit, Michigan

  • Nebraska Hematology - Oncology, P.C.

    Lincoln, Nebraska

  • Oncology Hematology West PC dba Nebraska Cancer Specialists

    Omaha, Nebraska

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • New York Oncology Hematology, P.C. - Albany

    Albany, New York

  • Queens Hospital Cancer Center

    Jamaica, New York

  • Coleman, Pasmantier & Decter, MDs

    New York, New York

  • Weill Cornell Medicine/New York-Presbyterian Hospital

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • Hematology/Oncology Associates of Central New York

    Syracuse, New York

Showing 40 of 235 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.